Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hester Biosciences Limited (HESTERBIO.NS)
Ahmedabad, IN
Hester Biosciences Limited, founded in 1987 and headquartered in Ahmedabad, India, specializes in the production and commercialization of veterinary vaccines and a comprehensive array of animal health solutions. The company's operations span both domestic and international markets, structured around two primary divisions: Poultry Healthcare and Animal Healthcare. Its extensive range of poultry vaccines targets numerous conditions, including Newcastle disease, infectious bronchitis, infectious bursal disease, fowl pox, egg drop syndrome, reovirus infections, Marek's disease, infectious coryza, fowl cholera, mycoplasma gallisepticum, inclusion body hepatitis, and avian encephalomyelitis. For larger animals, Hester Biosciences provides vaccines designed to combat ailments such as Goat Pox, Peste des Petits Ruminants (PPR), Brucellosis, Mastitis, Metritis, various infectious diseases, reproductive disorders, theileriosis, and parasitic infestations. Beyond vaccines, the company's product portfolio encompasses vital feed supplements like toxin binders, trace minerals, enzyme preparations, and bypass fats. It also supplies disinfectants for maintaining farm hygiene and sanitizing equipment, along with water purification solutions. Nutritional support products are offered, including mineral mixtures, fertility boosters, and growth tonics. A significant portion of their offerings consists of herbal preparations, featuring growth promoters, natural alternatives to choline chloride, stress and immunity enhancers, respiratory aids, liver tonics, wound healing agents, uterine and digestive tonics, anti-bloat remedies, ectoparasiticides, and treatments for anti-mastitis and anti-prolapse conditions.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.77% | +6.18% | +19.42% | +12.56% | +5.56% | +11.31% | -3.41% | +2.37% | -35.84% | +183.06% | +285.45% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+6.9% ★ Q1'26: +22.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+109.1% ★ Q1'26: +968.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+2.5% Q1'26: +9.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+20.4% ★ Q1'26: +28.4% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+9.2% ★ Q1'26: +13.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+1.5% Q1'26: +15.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.25× Q1'26: 1.42× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
906.35M
est: 914.05M (-0.8%)
|
1.01B
est: 1.02B (-1.6%)
|
1.23B
est: 1.21B (+2.2%)
|
1.36B
est: 1.37B (-0.7%)
|
1.78B
est: 1.67B (+6.5%)
|
1.83B
est: 1.85B (-0.9%)
|
2.14B
est: 2.00B (+7.4%)
|
2.35B
est: 2.41B (-2.4%)
|
2.66B
est: 2.69B (-0.9%)
|
3.05B
est: 3.02B (+0.9%)
|
3.11B
est: 3.39B (-8.3%)
|
| EBITDA |
251.84M
est: 232.34M (+8.4%)
|
340.12M
est: 260.52M (+30.6%)
|
414.34M
est: 306.34M (+35.3%)
|
498.17M
est: 348.13M (+43.1%)
|
752.45M
est: 425.11M (+77.0%)
|
617.68M
est: 469.96M (+31.4%)
|
700.21M
est: 507.37M (+38.0%)
|
731.93M
est: 649.66M (+12.7%)
|
619.20M
est: 760.96M (-18.6%)
|
582.46M
est: 767.41M (-24.1%)
|
649.76M
est: 862.73M (-24.7%)
|
| EBIT |
224.74M
est: 173.69M (+29.4%)
|
282.40M
est: 194.75M (+45.0%)
|
341.06M
est: 229.01M (+48.9%)
|
399.13M
est: 260.25M (+53.4%)
|
621.60M
est: 317.79M (+95.6%)
|
486.96M
est: 351.32M (+38.6%)
|
591.22M
est: 379.28M (+55.9%)
|
550.43M
est: 457.76M (+20.2%)
|
420.28M
est: 681.32M (-38.3%)
|
410.72M
est: 573.68M (-28.4%)
|
481.74M
est: 644.94M (-25.3%)
|
| Net Income |
124.66M
est: 138.86M (-10.2%)
|
188.83M
est: 166.52M (+13.4%)
|
234.48M
est: 232.30M (+0.9%)
|
256.21M
est: 283.97M (-9.8%)
|
415.67M
est: 409.93M (+1.4%)
|
291.71M
est: 471.65M (-38.2%)
|
344.30M
est: 219.81M (+56.6%)
|
393.20M
est: 397.76M (-1.1%)
|
266.27M
est: 465.91M (-42.8%)
|
188.89M
est: 328.50M (-42.5%)
|
274.88M
est: 432.32M (-36.4%)
|
| SGA |
73.17M
est: 156.82M (-53.3%)
|
148.19M
est: 175.84M (-15.7%)
|
188.51M
est: 206.77M (-8.8%)
|
175.39M
est: 234.97M (-25.4%)
|
247.83M
est: 286.93M (-13.6%)
|
342.34M
est: 317.20M (+7.9%)
|
447.23M
est: 342.45M (+30.6%)
|
247.26M
est: 413.31M (-40.2%)
|
316.64M
est: 1.22B (-74.1%)
|
581.07M
est: 517.96M (+12.2%)
|
728.49M
est: 582.30M (+25.1%)
|
| EPS |
16.00
est: 17.12 (-6.5%)
|
22.57
est: 20.53 (+9.9%)
|
27.68
est: 28.64 (-3.4%)
|
30.12
est: 35.01 (-14.0%)
|
48.86
est: 50.54 (-3.3%)
|
34.29
est: 58.15 (-41.0%)
|
40.47
est: 27.10 (+49.3%)
|
46.22
est: 47.20 (-2.1%)
|
31.30
est: 35.60 (-12.1%)
|
22.20
est: 40.50 (-45.2%)
|
32.31
est: 53.30 (-39.4%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Rajiv Dinesh Gandhi | Executive Chief Executive Officer, MD & Executive Director | 40M | male |
| Priya Gandhi | Executive Director | 8M | female |
| Ashish Dineshbhai Desai | Chief Financial Officer | — | male |
| Sulochana Shrestha | Chief Executive Officer of Hester Biosciences Nepal Private Limited | — | — |
| Upendra K. Jani | Consultant | — | — |
| Vinod Mali | Company Secretary & Compliance Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HESTERBIO.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
